Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Despina Fotiou

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|July 13, 2026
Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathiesEirini Solia, Foteini Theodorakakou, Panagiotis Malandrakis, et al.
British Journal of Haematology|August 24, 2020
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significanceEfstathios Kastritis, Foteini Theodorakakou, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2025
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study GroupEirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Cancers|September 10, 2021
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective StudyEvangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, et al.
American Journal of Hematology|May 19, 2025
Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL AmyloidosisFoteini Theodorakakou, Despina Fotiou, Filia Apostolakou, et al.
Cancers|November 7, 2020
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple MyelomaKonstantinos Papadimitriou, Nikolaos Tsakirakis, Panagiotis Malandrakis, et al.
American Journal of Hematology|April 4, 2017
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapyEfstathios Kastritis, Maria Gavriatopoulou, Maria Roussou, et al.
Blood Advances|December 11, 2019
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasoneEfstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Blood|February 2, 2018
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosisEfstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, et al.
Leukemia|February 16, 2021
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective studyEfstathios Kastritis, Ageliki Laina, Georgios Georgiopoulos, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|July 13, 2026
Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathiesEirini Solia, Foteini Theodorakakou, Panagiotis Malandrakis, et al.
British Journal of Haematology|August 24, 2020
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significanceEfstathios Kastritis, Foteini Theodorakakou, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2025
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study GroupEirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Cancers|September 10, 2021
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective StudyEvangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, et al.
American Journal of Hematology|May 19, 2025
Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL AmyloidosisFoteini Theodorakakou, Despina Fotiou, Filia Apostolakou, et al.
Cancers|November 7, 2020
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple MyelomaKonstantinos Papadimitriou, Nikolaos Tsakirakis, Panagiotis Malandrakis, et al.
American Journal of Hematology|April 4, 2017
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapyEfstathios Kastritis, Maria Gavriatopoulou, Maria Roussou, et al.
Blood Advances|December 11, 2019
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasoneEfstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Blood|February 2, 2018
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosisEfstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, et al.
Leukemia|February 16, 2021
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective studyEfstathios Kastritis, Ageliki Laina, Georgios Georgiopoulos, et al.
Pageof 11